Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
Research
[키워드] active cancer
acute respiratory syndrome
adjusted
age
all-cause mortality
analyses
Analysis
Antiviral
antiviral therapy
association
Cancer
Cancer therapy
case sery
Chemotherapy
clinical
Clinical characteristics
Clinical severity
collected
combination therapy
Comorbidities
Comorbidity
Coronavirus-2
COVID-19
COVID-19 in patient
COVID-19 severity
Cox regression
criteria
Cutoff
develop
died
disease severity
evaluate
Health Service
healthcare
Hematologic malignancy
hematologic neoplasms
Hematological malignancy
higher risk
hospital
Immunosuppression
Impact
Infection
IQR
leukemia
Long-term follow-up
lower mortality
lymphoid
male
monoclonal antibody
Mortality
myeloid malignancies
myeloproliferative neoplasm
Non-Hodgkin Lymphoma
outcome
Patient
patients
patients with COVID-19
Prognostic factor
reported
required
respiratory viral infection
Result
risk stratification
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
severity of COVID-19
Sex
shown
solid tumors
Spain
therapy
Treatment
[DOI] 10.1186/s13045-020-00970-7 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s13045-020-00970-7 PMC 바로가기 [Article Type] Research